{"id":"W4403228604","doi":"10.1038/s41591-024-03270-6","title":"Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"Sanofi Genzyme; Feinberg School of Medicine; Allergan; Genentech; National Institutes of Health; Mitsubishi Tanabe Pharma Corporation; Servier; Eisai; Newcastle University; University of Exeter; Parkinson's UK; Voyager Therapeutics; Jazz Pharmaceuticals; Prothena; Denali Therapeutics; Neurocrine Biosciences; Weston Brain Institute; H. Lundbeck A/S; Deutsches Zentrum für Neurodegenerative Erkrankungen; Sunovion; Deutsche Forschungsgemeinschaft; Roche; McGill University; Michael J. Fox Foundation for Parkinson's Research; Boston Scientific Corporation; Pfizer; Northwestern University; Biogen; Parkinson's Foundation; Celgene; Verily Life Sciences; Teva Pharmaceutical Industries; Sanofi; Parkinson Canada; F. Hoffmann-La Roche; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Placebo; Parkinson's disease; Medicine; Rating scale; Internal medicine; Levodopa; Disease; Motor symptoms; Psychology; Physical therapy; Physical medicine and rehabilitation; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002236775,0.0007413179,0.001688948,0.00016933,0.0003435836,0.0007379101,0.0004312324,0.0008791751,0.002443804],"category_scores_gemma":[0.002139161,0.0002251208,0.001342902,0.000155207,0.0006232131,0.0008306563,0.000364883,0.001826791,0.0003485034],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002693538,"about_ca_system_score_gemma":0.0004668105,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002761703,"about_ca_topic_score_gemma":0.0006701854,"domain_scores_codex":[0.9992663,0.0004248183,0.00004793297,0.00009145834,0.00006586931,0.0001035779],"domain_scores_gemma":[0.998769,0.0003300899,0.0003204263,0.0001446061,0.0001015847,0.000334386],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9431459,0.005809029,0.002965635,0.0006515813,0.001065419,0.0001548001,0.0001602671,0.0005423835,0.006483673,0.0002549867,0.0009827086,0.03778354],"study_design_scores_gemma":[0.6561273,0.2989672,0.03567166,0.0001467384,0.001153176,0.0003214635,0.0001056045,0.001100969,0.002478898,0.0005887976,0.003295132,0.00004307051],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946088,0.003267187,0.0001917253,0.000161168,0.0001171439,0.0002593015,0.0002875249,0.00003199419,0.001075167],"genre_scores_gemma":[0.9971817,0.0007737532,0.0003037532,0.0001811926,0.0001479646,0.0003521866,0.000435174,0.000005007556,0.000619348],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002443804,"threshold_uncertainty_score":0.01182932,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01829417493526915,"score_gpt":0.3593214530867688,"score_spread":0.3410272781514997,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}